40 results about "Fasting insulin" patented technology

A controller for an insulin infusion device includes a processor device and a memory element that cooperate to provide a processor-implemented closed-loop insulin limit module. The insulin limit module is operated to obtain: a fasting blood glucose value of a user; a total daily insulin value of the user; and fasting insulin delivery data that is indicative of insulin delivered to the user during a fasting period. The insulin limit module calculates a maximum insulin infusion rate for the user based on the fasting blood glucose value, the total daily insulin value, and the fasting insulin delivery data. The maximum insulin infusion rate is applicable during a period of closed-loop operation of the insulin infusion device.

Processor-implemented methods of controlling an insulin infusion device for a user are provided here. A first method obtains and analyzes calibration factors (and corresponding timestamp data) for a continuous glucose sensor, and regulates entry into a closed-loop operating mode of the infusion device based on the calibration factors and timestamp data. A second method obtains a most recent sensor glucose value and a target glucose setpoint value for the user at the outset of the closed-loop mode. The second method adjusts the closed-loop insulin infusion rate over time, in response to the sensor glucose value and the setpoint value. A third method calculates an upper insulin limit that applies to the insulin infusion rate during the closed-loop mode. The insulin limit is calculated based on a fasting blood glucose value of the user, a total daily insulin value of the user, and fasting insulin delivery data for the user.

The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L. The invention may be in the shape of a powder, capsules, pellets, tablets, effervescent tablets or food products comprising said protein composition.

A method of controlling an insulin infusion device comprises operating a processor architecture comprising at least one processor device to calculate a maximum insulin infusion rate for the user based on a fasting blood glucose value associated with the user, a total daily insulin value associated with the user, and fasting insulin delivery data that is indicative of insulin delivered to the user during a fasting period, wherein the maximum insulin infusion rate is applicable during a period of closed-loop operation of the insulin infusion device; obtaining a first closed-loop insulin infusion rate for the user, wherein the first closed- loop insulin infusion rate is obtained for a current sampling point during the period of closed- loop operation; and providing a second closed-loop insulin infusion rate for the user when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate, wherein the second closed-loop insulin infusion rate is less than the first closed-loop insulin infusion rate; the first closed-loop insulin infusion rate is calculated in accordance with a proportional-integral-derivative insulin feedback (PID-IFB) control algorithm; and inhibiting windup of an integral component of the PID-IFB control algorithm when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate.

The invention relates to a beverage, and particularly relates to a beverage containing a fresh ginseng juice. The beverage is prepared by squeezing fresh ginseng with addition of water and is sterilized by an ultrahigh pressure device. In vivo animal experiments show that the fresh ginseng juice can significantly reduce fasting blood glucose of 2-type diabetes, increase the fasting insulin level and improve the islet function.

The invention discloses a buccal tablet applicable to being taken for type II diabetes. The buccal tablet is prepared from the following components in parts by weight: 18-22 parts of island stichopus japonicas sea cucumber fucoidan chitosan sulfate, 17-19 parts of astragalus polysaccharide, 14-16 parts of rehmannia extract, 15-16 parts of tremella polysaccharide, 9-12 parts of microcrystalline cellulose, 7-9 parts of newtol, 7-9 parts of magnesium stearate, 4-5 parts of sodium citrate, and 0.3-0.5 part of peppermint essence. By adopting the buccal tablet disclosed by the invention, the fasting blood-glucose content of the mice with the type II diabetes can be obviously reduced; the tolerance dose of oral glucose is improved; C peptide and fasting insulin level in the blood are increased. Therefore, the buccal tablet has the advantages of being convenient to take, easy to store, high in bioavailability, convenient to carry, and suitable for living demands of fast-paced people.

The present disclosure relates to a method of inducing weight loss and/or preventing weight gain in a subject affected by administering certain diets selected based on the fasting blood glucose and/or the fasting insulin of the subject. The present disclosure further provides personalized dietary instruction, based on the fasting blood glucose and/or the fasting insulin of a subject, with the potential to improve the weight loss and prevent weight regain. The present disclosure further relates to methods for predicting weight loss success and classifying responsiveness of a subject to a certain diet as well as methods for selecting a weight loss or a weight gain diet for a subject based on the fasting blood glucose and/or the fasting insulin of the subject.

A method for evaluating insulin resistance in a simple and highly reliable manner is provided. This method comprises measuring a fasting insulin parameter in blood, a fasting blood sugar parameter, and an adiponectin parameter and evaluating insulin resistance using, as an index, a value obtained by the following calculation formula (I):

(Fasting insulin value)×(Fasting blood sugar value)/Adiponectin value   (I)

The application provides a traditional Chinese medicine composition and application thereof in preparation of a drug for treating IR and relates to the field of traditional Chinese medicines. The traditional Chinese medicine composition comprises: 30g of raw milkvetch roots, 30g of radix puerariae, 9g of raw radix notoginseng, 9g of rhizoma coptidis, 30g of raw rehmannia roots, 15g of radix angelicae sinensis, 30g of raw white peony roots, 30g of panicled swallowwort roots and 15g of corydalis tubers. The traditional Chinese medicine composition can be applied to preparation of drugs for treating insulin resistance, particularly insulin resistance of post-stroke myospasm sufferers; it is verified that after the composition is taken, motor functions of affected limbs of the post-stroke myospasm sufferer are restored obviously, and fasting blood-glucose, fasting insulin and insulin resistance levels are all improved effectively; and it is confirmed that the traditional Chinese medicine composition can be applied to the preparation of the drugs for treating the insulin resistance of the post-stroke myospasm sufferers.

The invention discloses a kidney tonifying and turbidity eliminating Chinese medicine composition and application thereof, and belongs to the technical field of pharmaceutical preparations. An active component of the kidney tonifying and turbidity eliminating Chinese medicine composition is prepared from, by weight, herba patriniae, raw coicis semen, talxilli herba, dipsaci radix, raw gypsum, cuscutae semen, poria cocos, pseudostellariae radix, lycopi herba, persicae semen, fructus aurantii and fried licorice root. The kidney tonifying and turbidity eliminating Chinese medicine composition takes kidney tonifying, spleen strengthening, turbidity eliminating and menstruation regulating as therapeutic rules, the fasting insulin level of a PCOS-IR rat can be significantly reduced, endocrine disorder conditions such as hyperandrogenism, LH increasing, abnormal LH/FSH ratios are improved, and polycystic-ovary-like lesions can also be rectified to a certain degree.

The invention provides application of a pharmaceutical composition to preparation of medicines for treating type 2 diabetes mellitus, and the pharmaceutical composition is prepared from the followingraw materials by a weight ratio: 2-10 parts of rhizoma coptidis and 1-10 parts of fructus evodiae. The composition provided by the invention can effectively improve the levels of fasting plasma glucose (FPG), fasting insulin (FINS) and OGTT2h plasma glucose (OGTT2hPG) in patients with the type 2 diabetes mellitus, and does not have an adverse effect; therefore, a new choice is provided for clinical medication.